Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108LYoshiko Urata, Yoichi Nakanishi, Miyako Satouchi et al.|Journal of Clinical Oncology|2016Cited by 160
Bevacizumab beyond disease progression after first‐line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non–small cell lung cancer (<scp>W</scp>est <scp>J</scp>apan <scp>O</scp>ncology <scp>G</scp>roup 5910L): An open‐label, randomized, phase 2 trialMasayuki Takeda, Isamu Okamoto, Takeharu Yamanaka et al.|Cancer|2016Cited by 42
Randomized phase III study comparing gefitinib (G) with erlotinib (E) in patients (pts) with previously treated advanced lung adenocarcinoma (LA): WJOG 5108L.Nobuyuki Katakami, Satoshi Morita, Hiroshige Yoshioka et al.|Journal of Clinical Oncology|2014Cited by 11
Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy inadvanced nonsquamous non–small cell lung cancer (WJOG 5910L): An open-label, randomized, phase II trial.Masayuki Takeda, Takashi Seto, Hidetoshi Hayashi et al.|Journal of Clinical Oncology|2015Cited by 3